Highline Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

Highline Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.5K	Hold	1,000	–	–	0.01%	222
2026 Q1	$47.6K	Hold	1,000	–	–	0.01%	182
2025 Q4	$52.4K	Hold	1,000	–	–	0.01%	134
2025 Q3	$64.8K	Hold	1,000	–	–	0.02%	146
2025 Q2	$48.6K	Hold	1,000	–	–	0.01%	147
2025 Q1	$34K	Hold	1,000	–	–	0.01%	157
2024 Q4	$39.4K	Buy	+1,000	New	+$47.2K	0.01%	141

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Highline Wealth Partners's CRSP Position: Q2 2026 in Review

Highline Wealth Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 1,000 shares worth $54.5K. The position accounts for 0.01% of the portfolio, ranked #222.

Highline Wealth Partners first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. The position peaked at $64.8K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Highline Wealth Partners held 1,000 shares of CRISPR Therapeutics worth $54.5K as of Q2 2026.
Highline Wealth Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up 0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #222 holding.
Highline Wealth Partners first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
Highline Wealth Partners's CRISPR Therapeutics position peaked at $64.8K in Q3 2025.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.